Drug Trial Radar · NCT00707538
A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress
Last checked: Nov 20, 2026Latest source record: Nov 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Jun 2008
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Lantheus Medical ImagingIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to learn the biodistribution of injection of BMS747158 at stress and assess the safety of two doses of BMS747158
Conditions
- Healthy Volunteers
Interventions
BMS747158Drug
2 IV injection of \~11 mCi (total) F-18 labeled compound
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dosimetry analysis following whole body imaging after stress injectionTime frame: Imaging takes place approximately 0 - 300 minutes post injection
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
John Hopkins University
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.